




## Product Introduction

### YM201636

YM201636 is a selective **PIKfyve** inhibitor with **IC50** of 33 nM, less potent to p110 $\alpha$  and insensitive to FabI (yeast orthologue).

#### Technical Data:

<b>Molecular Weight (MW):</b>	467.48	
<b>Formula:</b>	C <sub>25</sub> H <sub>21</sub> N <sub>7</sub> O <sub>3</sub>	
<b>Solubility (25°C)</b>	DMSO 35 mg/mL	
<b>* &lt;1 mg/ml means slightly soluble or insoluble:</b>	Water <1 mg/mL	
	Ethanol <1 mg/mL	
<b>Purity:</b>	>98%	
<b>Storage:</b>	3 years -20°C Powder 6 months -80°C in DMSO	
<b>CAS No.:</b>	371942-69-7	

#### Biological Activity

YM201636 potently inhibits mammalian PIKfyve with an IC<sub>50</sub> of 33 nM but not yeast orthologue Fab1 with an IC<sub>50</sub> of >5  $\mu$ M, exhibiting around 100-fold selectivity for PtdIns3P p110 $\alpha$  with an IC<sub>50</sub> of 3  $\mu$ M. YM201636 (0.8  $\mu$ M) significantly decreases the production of PtdIns(3,5)P<sub>2</sub> by 80% in serum-starved NIH3T3 cells followed by serum stimulation with no effect on serum-stimulated protein kinase B (PKB) Ser 473 phosphorylation. YM-201636 reversibly impairs endosomal trafficking in NIH3T3 cells by blocking PIKfyve and PtdIns(3,5)P<sub>2</sub> production, mimicking the effect produced by depleting PIKfyve with siRNA.

Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.

YM-201636 (0.8  $\mu\text{M}$ ) also significantly reduces retroviruses budding from cells by 80%, apparently through interfering with the endosomal sorting complex required for transport (ESCRT) machinery. <sup>[1]</sup> In 3T3L1 adipocytes, YM-201636 inhibits basal and insulin-activated 2-deoxyglucose uptake with an IC<sub>50</sub> of 54 nM, with almost complete inhibition at doses as low as 160 nM. YM-201636 (0.1  $\mu\text{M}$ ) has also been shown to completely block insulin-dependent activation of class IA PI 3-kinase. <sup>[2]</sup> Although not involved in NPM-ALK-dependent proliferation and migration, YM201636 (0.4  $\mu\text{M}$ ) strongly reduces invasive capacities of NPM-ALK-expressing cells and their capacity to degrade the extracellular matrix. <sup>[3]</sup> YM201636 treatment blocks the continuous recycling of junctional proteins claudin-1 and claudin-2 in MDCK cells, leading to the intracellular accumulation and delay of epithelial barrier formation. <sup>[4]</sup>

## References

- [1] Jefferies HB, et al. EMBO Rep, 2008, 9(2), 164-170.
- [2] Ikonov OC, et al. Biochem Biophys Res Commun, 2009, 382(3), 566-570.
- [3] Dupuis-Coronas S, et al. J Biol Chem, 2011, 286(37), 32105-32114.
- [4] Dukes JD, et al. PLoS One, 2012, 7(3), e28659.



Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.

Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.